P0 P1 P2 P3 Change P1-P3
1997-2001 2002-2006 2007-2011 2012-2017 P-value
Women Women
Total N (per 100 000) 159 (12.7) 321 (25.7) 226 (18.1) 212 (17.0)
RR 0.50 1 0.70 0.66 <.01
NMBA N (%) 148 (93) 239 (74) 168 (74) 137 (65)
RR 1.13 1 1.00 0.92 0.02
IgE-SUX N (%) 31 (19) 54 (17) 21 (9) 9 (4)
RR 1.13 1 0.59 0.28 <.01
IgE-HEX N (%) 22 (14) 35 (11) 18 (8) 16 (8)
RR 1.24 1 0.75 0.71 0.25
Men Men
Total N (per 100 000) 66 (5.3) 131 (10.5) 123 (9.8) 141 (11.3)
RR 0.50 1 0.94 1.08 0.58
NMBA N (%) 55 (83) 100 (76) 77 (63) 99 (70)
RR 1.05 1 0.89 0.95 0.31
IgE-SUX N (%) 8 (12) 15 (11) 8 (7) 4 (3)
RR 1.05 1 0.59 0.27 0.01
IgE-HEX N (%) 8 (12) 19 (13) 28 (23) 13 (9)
RR 0.85 1 1.46 0.66 0.24
Sum of respective reporting variables per period. RR = relative risk of variable occurring compared with baseline period P1. Total = total number of reports, NMBA = number of reactions where neuromuscular blocking agents were used, IgE-SUX and IgE-HEX = number of reactions where the presence of serum IgE antibodies to SUX and HEX (≥0.35 kUA/l), respectively, was documented at the time of reaction. Of the parenthesized values, NMBA, IgE-SUX and IgE-HEX is calculated percentages from total, while parenthesized values of Total denote cases per 100 000 anesthesias. The statistics are calculated using 500 000 stipulated general anesthesias per year. † Chi-squared test. Sum of respective reporting variables per period. RR = relative risk of variable occurring compared with baseline period P1. Total = total number of reports, NMBA = number of reactions where neuromuscular blocking agents were used, IgE-SUX and IgE-HEX = number of reactions where the presence of serum IgE antibodies to SUX and HEX (≥0.35 kUA/l), respectively, was documented at the time of reaction. Of the parenthesized values, NMBA, IgE-SUX and IgE-HEX is calculated percentages from total, while parenthesized values of Total denote cases per 100 000 anesthesias. The statistics are calculated using 500 000 stipulated general anesthesias per year. † Chi-squared test. Sum of respective reporting variables per period. RR = relative risk of variable occurring compared with baseline period P1. Total = total number of reports, NMBA = number of reactions where neuromuscular blocking agents were used, IgE-SUX and IgE-HEX = number of reactions where the presence of serum IgE antibodies to SUX and HEX (≥0.35 kUA/l), respectively, was documented at the time of reaction. Of the parenthesized values, NMBA, IgE-SUX and IgE-HEX is calculated percentages from total, while parenthesized values of Total denote cases per 100 000 anesthesias. The statistics are calculated using 500 000 stipulated general anesthesias per year. † Chi-squared test. Sum of respective reporting variables per period. RR = relative risk of variable occurring compared with baseline period P1. Total = total number of reports, NMBA = number of reactions where neuromuscular blocking agents were used, IgE-SUX and IgE-HEX = number of reactions where the presence of serum IgE antibodies to SUX and HEX (≥0.35 kUA/l), respectively, was documented at the time of reaction. Of the parenthesized values, NMBA, IgE-SUX and IgE-HEX is calculated percentages from total, while parenthesized values of Total denote cases per 100 000 anesthesias. The statistics are calculated using 500 000 stipulated general anesthesias per year. † Chi-squared test. Sum of respective reporting variables per period. RR = relative risk of variable occurring compared with baseline period P1. Total = total number of reports, NMBA = number of reactions where neuromuscular blocking agents were used, IgE-SUX and IgE-HEX = number of reactions where the presence of serum IgE antibodies to SUX and HEX (≥0.35 kUA/l), respectively, was documented at the time of reaction. Of the parenthesized values, NMBA, IgE-SUX and IgE-HEX is calculated percentages from total, while parenthesized values of Total denote cases per 100 000 anesthesias. The statistics are calculated using 500 000 stipulated general anesthesias per year. † Chi-squared test. Sum of respective reporting variables per period. RR = relative risk of variable occurring compared with baseline period P1. Total = total number of reports, NMBA = number of reactions where neuromuscular blocking agents were used, IgE-SUX and IgE-HEX = number of reactions where the presence of serum IgE antibodies to SUX and HEX (≥0.35 kUA/l), respectively, was documented at the time of reaction. Of the parenthesized values, NMBA, IgE-SUX and IgE-HEX is calculated percentages from total, while parenthesized values of Total denote cases per 100 000 anesthesias. The statistics are calculated using 500 000 stipulated general anesthesias per year. † Chi-squared test. Sum of respective reporting variables per period. RR = relative risk of variable occurring compared with baseline period P1. Total = total number of reports, NMBA = number of reactions where neuromuscular blocking agents were used, IgE-SUX and IgE-HEX = number of reactions where the presence of serum IgE antibodies to SUX and HEX (≥0.35 kUA/l), respectively, was documented at the time of reaction. Of the parenthesized values, NMBA, IgE-SUX and IgE-HEX is calculated percentages from total, while parenthesized values of Total denote cases per 100 000 anesthesias. The statistics are calculated using 500 000 stipulated general anesthesias per year. † Chi-squared test.